BCTX (Briacell Therapeutics Corp. Common Shares) Stock Analysis - News
Briacell Therapeutics Corp. Common Shares (BCTX) is a publicly traded Healthcare sector company. As of May 21, 2026, BCTX trades at $3.78 with a market cap of $24.29M and a P/E ratio of -0.06. BCTX moved +9.69% today. Year to date, BCTX is -49.28%; over the trailing twelve months it is -89.10%. Its 52-week range spans $2.98 to $214.50. Rallies surfaces BCTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in BCTX news today?
BriaCell Adds Next-Gen Ovarian Cancer Immunotherapy Bria-OVA+ After Phase 2 Breast Success: BriaCell has expanded its pipeline to include Bria-OVA+, a next-generation personalized immunotherapy candidate for ovarian cancer designed with additional immune-stimulating components. The company has licensed ovarian cancer cell lines and commenced development following encouraging Phase 2 efficacy and tolerability results in advanced metastatic breast cancer.
Lustig Marc bought 902.93K (~$2.00M) on May 14, 2024.
Bondarenko Jamieson bought 28.00K (~$128.24K) on Dec 28, 2022.
Bondarenko Jamieson bought 22.00K (~$117.70K) on Dec 20, 2022.
BCTX Analyst Consensus
BCTX analyst coverage data. Average price target: $0.00.
Common questions about BCTX
What changed in BCTX news today?
BriaCell Adds Next-Gen Ovarian Cancer Immunotherapy Bria-OVA+ After Phase 2 Breast Success: BriaCell has expanded its pipeline to include Bria-OVA+, a next-generation personalized immunotherapy candidate for ovarian cancer designed with additional immune-stimulating components. The company has licensed ovarian cancer cell lines and commenced development following encouraging Phase 2 efficacy and tolerability results in advanced metastatic breast cancer.
Does Rallies summarize BCTX news?
Yes. Rallies summarizes BCTX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is BCTX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BCTX. It does not provide personalized investment advice.
